{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:06:28Z","timestamp":1782475588828,"version":"3.54.5"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T00:00:00Z","timestamp":1569196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00944","type":"journal-article","created":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T14:18:13Z","timestamp":1569248293000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis"],"prefix":"10.3389","volume":"9","author":[{"given":"Mike","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Rafiqul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shueh Wen","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Tamjid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1586\/era.09.25","article-title":"Current systemic therapy for metastatic melanoma","volume":"9","author":"Agarwala","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"key":"B17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.pharmthera.2017.07.005","article-title":"Toxicity profiles of immunotherapy","volume":"181","author":"Cousin","year":"2018","journal-title":"Pharmacol Therap"},{"key":"B18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/00004397-200004000-00014","article-title":"Appraisal and management of ocular hypotony and glaucoma associated with uveitis","volume":"40","author":"Tran","year":"2000","journal-title":"Int Ophthalmol Clin"},{"key":"B19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40123-015-0037-z","article-title":"Hypotony maculopathy: clinical presentation and therapeutic methods","volume":"4","author":"Thomas","year":"2015","journal-title":"Ophthalmol Therap"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.jcjo.2015.09.008","article-title":"Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: Case report","volume":"51","author":"Basilious","year":"2016","journal-title":"Can J Ophthalmol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.5301\/ejo.5000724","article-title":"A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab","volume":"26","author":"Abu Samra","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1002\/phar.1839","article-title":"A rare case of pembrolizumab-induced uveitis in a patient with metastatic melanoma","volume":"36","author":"Hanna","year":"2016","journal-title":"Pharmacotherapy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14737140.2017.1296765","article-title":"Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review","volume":"17","author":"Abdel-Rahman","year":"2017","journal-title":"Expert Rev Anticancer Therap"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur Respirat J"},{"key":"B26","first-page":"A6599","article-title":"Nivolumab induced multi-organ dysfunction: pneumonitis, cardiomyopathy and hepatitis","volume":"197","author":"Chandak","year":"2018","journal-title":"Am J Respir Crit Care Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"10063","DOI":"10.1200\/JCO.2018.36.15_suppl.10063","article-title":"Outcomes of immune-checkpoint inhibitor induced organ toxicities","volume":"36","author":"Abu Sbeih","year":"2018","journal-title":"J Clin Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","article-title":"Durable Complete response after discontinuation of pembrolizumab in patients with metastatic melanoma","volume":"36","author":"Robert","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00944\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T14:18:19Z","timestamp":1569248299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00944\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,23]]},"references-count":29,"alternative-id":["10.3389\/fonc.2019.00944"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00944","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,23]]},"article-number":"944"}}